Breast Cancer
Online ISSN : 1880-4233
Print ISSN : 1340-6868
ISSN-L : 1340-6868
Case Reports
A Case of Metastatic Breast Cancer with HER2 Gene Amplification that Responded Completely to Single Agent Trastuzumab
Yasuhiro TsutaniShozo OhsumiKenjiro AogiNaruto TairaMasaaki KataokaYasushi HamamotoRieko Nishimura Rieko NishimuraShigemitsu Takashima
Author information
JOURNAL FREE ACCESS

2006 Volume 13 Issue 4 Pages 374-377

Details
Abstract
An 80-year-old woman visited our hospital with a massive ulcerated tumor in the upper lateral quadrant of the right breast. Her performance status was 2. Histopathologically, a mass consisting of a huge primary tumor and metastatic axillary lymph nodes was seen and invasive ductal carcinoma was diagnosed. Both estrogen and progesterone receptors were negative. Herceptest® (DakoCytomation, Glostrup, Denmark) showed 2 + staining and HER2 amplification was detected by fluorescent in situ hybridization. CT revealed multiple lung metastases. Her old age and performance status of 2 made aggressive chemotherapy difficult. After receiving 5'-DFUR 600 mg/day as the first line treatment for two months, the tumors progressed. As second-line treatment, single agent therapy with a loading dose, a trastuzumab 4 mg/kg followed by 2 mg/kg weekly was recommended. The patient also received 60 Gy radiotherapy. Six months after the second line treatment, the breast tumor disappeared and only a scar remained on the chest wall and axilla. CT showed no lung tumors. During the trastuzumab treatment, no adverse effect was observed. Her performance status improved to zero, and she is alive and free from the disease 24 months after the disappearance of the tumor.
Content from these authors

This article cannot obtain the latest cited-by information.

© 2006 by The Japanese Breast Cancer Society
Previous article Next article
feedback
Top